BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ivarmacitinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ivarmacitinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04957550-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20261213
DTEND;VALUE=DATE:20261214
SUMMARY:ivarmacitinib: Phase 3 readout est. (NCT04957550)
DESCRIPTION:ivarmacitinib\, phase 3.\nStudy: To Evaluate the Efficacy and S
 afety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis\nEstimat
 ed primary completion: 13 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04957550
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381114-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:ivarmacitinib: Phase 1/2 readout est. (NCT07381114)
DESCRIPTION:ivarmacitinib\, phase 1/2.\nStudy: A Clinical Study on the Effi
 cacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Tra
 nsplantation\nEstimated primary completion: 30 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07381114
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925048-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT06925048)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: SHR0302 Combined With PD-1/PD-
 L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSC
 LC\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06925048
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06519526-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT06519526)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: Exploratory Clinical Study of 
 SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Ce
 ll Lymphoma\nEstimated primary completion: 28 February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ivarmacitinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06519526
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07251595-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT07251595)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: A Trial of SHR0302 Tablets and
  SHR0302 Base Gel in Patients With Non-segmental Vitiligo\nEstimated prima
 ry completion: March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ivarmacitinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07251595
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731153-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT06731153)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: JAK1 Inhibitor Ivarmacitinib R
 eversing Immunotherapy Resistance in TNBC\nEstimated primary completion: J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivarmacitin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6731153
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550452-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:ivarmacitinib: Phase na readout est. (NCT07550452)
DESCRIPTION:ivarmacitinib\, phase na.\nStudy: Efficacy and Safety of Switch
 ing to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis
  With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibit
 ors: A Prospective\, Multicenter\, Real-World Study\nEstimated primary com
 pletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ivarmacitinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07550452
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896096-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT07896096)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: Ivarmacitinib Combined With Ca
 mrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer
  After Failure of Second-line or Later Treatment\nEstimated primary comple
 tion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ivarmacitinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07896096
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266168-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:ivarmacitinib: Phase na readout est. (NCT07266168)
DESCRIPTION:ivarmacitinib\, phase na.\nStudy: Efficacy and Safety of Ivarma
 citinib in the Treatment of Patients With Polymyalgia Rheumatica\nEstimate
 d primary completion: 30 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07266168
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07313202-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT07313202)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: Ivarmacitinib in Advanced Soli
 d Tumors: A Prospective\, Two-Cohort\, Two-Phase Exploratory Study in Pati
 ents Discontinued Due to Immune Intolerance\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iv
 armacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07313202
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324473-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT07324473)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: Ivarmacitinib Combined With Ca
 mrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma
  With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Explo
 ratory Clinical Study\nEstimated primary completion: 1 January 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ivarmacitinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07324473
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07452445-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:ivarmacitinib: Phase 4 readout est. (NCT07452445)
DESCRIPTION:ivarmacitinib\, phase 4.\nStudy: Efficacy and Safety of Ivarmac
 itinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis\nE
 stimated primary completion: 1 March 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07452445
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814664-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:ivarmacitinib: Phase 2/3 readout est. (NCT07814664)
DESCRIPTION:ivarmacitinib\, phase 2/3.\nStudy: Ivarmacitinib Versus Glucoco
 rticoids in Mild-to-Moderate Systemic Lupus Erythematosus\nEstimated prima
 ry completion: 30 March 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ivarmacitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07814664
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941778-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:ivarmacitinib: Phase 2/3 readout est. (NCT07941778)
DESCRIPTION:ivarmacitinib\, phase 2/3.\nStudy: Ivarmacitinib Treat PMR\nEst
 imated primary completion: 30 March 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07941778
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276620-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:ivarmacitinib: Phase na readout est. (NCT07276620)
DESCRIPTION:ivarmacitinib\, phase na.\nStudy: Treatment of Moderate-to-Seve
 re Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults\nEstimat
 ed primary completion: 30 April 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07276620
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570745-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT07570745)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: Low-Dose ATG/PTCy Plus Ivarmac
 itinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors\nEsti
 mated primary completion: 1 May 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07570745
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505186-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT07505186)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: Camrelizumab\, Chemotherapy an
 d Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carci
 noma\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07505186
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07451665-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:ivarmacitinib: Phase 4 readout est. (NCT07451665)
DESCRIPTION:ivarmacitinib\, phase 4.\nStudy: Efficacy and Safety of Vunakiz
 umab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis\nEs
 timated primary completion: 31 March 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07451665
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845955-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT07845955)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: JAK1 Inhibitor Ivarmacitinib f
 or Improving Pancreatic Islet Function in T1D\nEstimated primary completio
 n: 31 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iv
 armacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07845955
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07894497-29@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:ivarmacitinib: Phase 4 readout est. (NCT07894497)
DESCRIPTION:ivarmacitinib\, phase 4.\nStudy: Ivarmacitinib With or Without 
 Celecoxib for Ankylosing Spondylitis\nEstimated primary completion: 31 Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivarmacit
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07894497
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
